Abstract
Envafolimab ((sic)(sic)(R)) is a subcutaneously (SC) administered single domain anti-programmed death ligand 1 (PD-L1) antibody being developed for th......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
